Press release
Lawsuit filed for Investors who lost money with shares of Metagenomi, Inc. (NASDAQ: MGX)

A lawsuit was filed on behalf of investors in Metagenomi, Inc. (NASDAQ: MGX) shares over alleged securities laws violations.
Investors who purchased shares of Metagenomi, Inc. (NASDAQ: MGX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 25, 2024. NASDAQ: MGX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Emeryville, CA based Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
On February 12, 2024, Metagenomi, Inc. conducted its initial public offering ("IPO"). The Company sold about 6.25 million shares at $15 per share as part of the IPO.
Then on May 1, 2024, Metagenomi, Inc. announced that it and Moderna had "mutually agreed to terminate their collaboration" agreement. An analyst reported on the announcement, noting that the news was surprising, as was its timing. The analyst also noted that the partnership Metagenomi had with Moderna was a critical part of the core thesis and that losing this partnership during this early stage in development raised more questions than answers.
Shares of Metagenomi, Inc. (NASDAQ: MGX) declined to as low as $2.76 per share on August 09, 2024.
The plaintiff alleges on behalf of purchasers who purchased Metagenomi, Inc. (NASDAQ: MGX) shares pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 9 and 13, 2024, the Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. The action seeks to compensate the Class members and recover the damages they sustained because of Defendants' allegedly false and misleading statements.
Those who purchased shares of Metagenomi, Inc. (NASDAQ: MGX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Metagenomi, Inc. (NASDAQ: MGX) here
News-ID: 3742431 • Views: …
More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…

Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…

CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…

Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Metagenomi
Long Term Investors in shares of Metagenomi, Inc. (NASDAQ: MGX) should contact t …
An investigation on behalf of current long-term investors in shares of Metagenomi, Inc. (NASDAQ: MGX) concerning potential breaches of fiduciary duties by certain directors and officers of Metagenomi, Inc. was announced.
Investors who are current long term investors in Metagenomi, Inc. (NASDAQ: MGX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Investigation announced for Long Term Investors in shares of Metagenomi, Inc. (N …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Metagenomi, Inc.
Investors who are current long term investors in Metagenomi, Inc. (NASDAQ: MGX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: MGX stocks follows a lawsuit filed against Metagenomi, Inc. over…
Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
In a world where healthcare innovation is accelerating, companies leveraging artificial intelligence are leading the charge in transforming patient care, diagnostics, and therapeutic solutions. Their advancements in smart disinfection, AI-designed therapies, precision gene editing, and cardiovascular diagnostics are not only reshaping their industries but also unlocking tremendous growth potential. Here's how these cutting-edge companies are redefining the future of healthcare.
CS Diagnostics Corp. (OTCQB: CSDX) Launches Next-Gen Disinfectant MEDUSA a cutting-edge…
Lawsuit filed for Investors who lost money with Metagenomi, Inc. (NASDAQ: MGX) i …
An investor, who purchased shares of Metagenomi, Inc. (NASDAQ: MGX), filed a lawsuit over alleged violations of Federal Securities Laws by Metagenomi, Inc. in connection with certain allegedly false and misleading statements made between February 9 and 13, 2024.
Investors who purchased a significant amount of shares of Metagenomi, Inc. (NASDAQ: MGX) between February 9 and 13, 2024, have certain options and for certain investors are short and strict deadlines running.…
Investigation announced for Investors in shares of Metagenomi, Inc. (NASDAQ: MGX …
An investigation was announced for investors of Metagenomi, Inc. (NASDAQ: MGX) shares over potential securities laws violations by Metagenomi, Inc.
Investors who purchased shares of Metagenomi, Inc. (NASDAQ: MGX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Metagenomi, Inc. (NASDAQ: MGX) concerning whether a series…
U.S. GENE EDITING MARKET IS EXPECTED TO REACH USD 9.16 BILLION BY 2027 - ARIZTON
Genome editing aims to modify the DNA sequence so cells can make the correct protein again. NIH created the SCGE program in January 2018 to improve genome editing technology and make genome editing therapies more widely available. Genome editing has a great potential to change the treatment environment for both common and rare diseases. Gene editing is in its infancy, and these newly funded projects promise better strategies to address…